Agilent closes $240 million Proscia deal, owns its pathology software

Agilent Technologies paid $240 million in cash on Nov. 4 to complete its acquisition of Proscia, taking ownership of the digital pathology software it had distributed since September 2022. The Santa Clara, Calif., company is offering up to $30 million more tied to future performance milestones, and Proscia now sits inside its Life Sciences and Diagnostics Markets Group.

The price is modest against the revenue Agilent disclosed. Proscia carried trailing 12-month revenue above $18 million when the deal was announced on Oct. 13, and it serves more than 4,000 laboratories, hospitals and clinics as well as 16 of the top 20 pharmaceutical companies. Agilent, which reported $6.95 billion in revenue for fiscal 2025, put the pathology market at $5 billion. The closing landed early in Agilent's fiscal 2027, which began Nov. 1 — a fast turnaround by deal standards.

What does Agilent actually gain?

Concentriq, a platform for managing and reviewing digital images of tissue samples, is the core asset. Agilent describes it as a central operating layer for digital pathology: it connects slide scanners, lab information systems, image-analysis applications and AI tools, and it works with scanners from multiple vendors rather than locking labs into one hardware line. For R&D managers, that vendor-neutrality matters; it preserves existing scanner fleets during any integration.

The software carries regulatory weight. Concentriq AP-Dx, the clinical version, received FDA 510(k) clearance for primary diagnosis in February 2024, paired with Hamamatsu's NanoZoomer S360MD slide scanner. A second clearance, reported Aug. 10, 2026 by CAP Today, added Leica's Aperio GT 450 DX scanner and cloud deployment. It also included a predetermined change control plan, allowing Proscia to validate and add other FDA-cleared scanners, image formats and displays without filing a new 510(k) each time — a meaningful cost lever for future expansion.

Where does the AI claim stand?

Agilent President and CEO Padraig McDonnell framed the strategic logic in October: "The acquisition establishes an Agilent platform for scientific intelligence in tissue-based precision medicine, connecting data generation with AI-based interpretation in a workflow that supports biomarker research through routine clinical use."

The claim rests on measurable assets. Proscia's repository holds more than 12 million de-identified tissue images linked to clinical and genomic records, according to figures the company gave in September 2025 when it launched Aperture, an AI platform that flags likely clinical-trial candidates when a pathologist signs out a diagnosis. Proscia also said its Concentriq lab network was on track for about 8 million pathology diagnoses that year, and it listed Agilent as Aperture's partner for end-to-end workflow distribution. Later that month, Proscia said it would add Pictor Labs' virtual H&E, IHC and special stains to Concentriq for research use. Agilent argues this data pool creates AI-enabled synergies with its companion diagnostics business for biopharma partners and clinical and translational research customers — a projection, not yet a measured result.

David West, Proscia's co-founder and CEO, endorsed the fit. "Agilent shares our vision for advancing pathology through open, digital, and AI-enabled solutions," he said. "Together, we can accelerate innovation while continuing to provide customers with the flexibility they need across clinical and life-sciences workflows."

Is this a one-off or a pattern?

It is the second pathology acquisition Agilent has made in 2026. On March 9, the company agreed to acquire Biocare Medical for $950 million in cash and completed the deal before announcing the Proscia agreement. Biocare makes more than 300 specialized antibodies, plus immunohistochemistry, in situ hybridization and fluorescence in situ hybridization products for oncology and clinical pathology.

Proscia arrived with independent validation of a sort. KLAS Research named it 2026 Best in KLAS for digital pathology, with the highest performance score in both the U.S. and European markets, according to Agilent. The Philadelphia company, founded in 2014, had raised a $50 million Series C round led by Insight Partners in March 2025, bringing total funding to $130 million — a multiple Agilent is now paying roughly 1.8 times beyond in a single cash transaction.

With Concentriq under direct ownership, Agilent can now bundle staining instruments, antibodies, software and AI-driven diagnostics into one portfolio, and the first test of that integration will come as the milestone-linked $30 million earns out.